Healthcare >> CEO Interviews >> June 2, 2004

Christopher Searcy – Nektar Therapeutics (nktr)

CHRISTOPHER J. SEARCY is Vice President of Corporate Development at Nektar Therapeutics. He joined Nektar when it was still named Inhale in 1996. Previously, Dr. Searcy was the Vice President of Business Development of GalaGen, Inc., an oral antibody company focusing on human gastrointestinal tract infections. From 1985 to 1995, Dr. Searcy held various positions in registration and regulatory affairs, clinical research and marketing at Pfizer Inc. In his last position at Pfizer, he was the Director of Licensing and Development. Dr. Searcy holds a BS in Pharmacy and a PharmD both from the University of Minnesota, and an MBA from the University of Pennsylvania, Wharton School. Profile
TWST: Can we start with a quick overview of Nektar?

Dr. Searcy: Nektar provides novel drug delivery technologies for

transforming therapeutics into high-value, differentiated products.

Nektar